Document is current

Article History

Received: 15 December 2023

Accepted: 19 June 2024

First Online: 2 July 2024

Change Date: 13 August 2025

Change Type: Update

Change Details: This research has been updated following the post-publication peer rerview.

Declarations

:

: This is a retrospective cohort study and was conducted using data from the Clinformatics® Data Mart database and therefore did not qualify for/require ethics approval or consent to participate. All data analyzed during this study are from the Clinformatics Data Mart database that is cited in the Methods section. The study utilizes the secondary use of commercially available de-identified healthcare data. Identifiable patient information has been stripped and determined to be de-identified in accordance with the HIPAA Privacy Rule by either expert determination (§ 164.514 (b)(1)) or Safe Harbor (§ 164.514 (b)(2)). The use of data would not constitute human subjects research in accordance with the Common Rule (45 CFR 46.102(f)). Therefore, institutional review board review was not required.

: Not applicable.

: S.Y. conducted the analysis and writing as an intern and contractor for Regeneron Pharmaceuticals, Inc.C.K. is an employee of and shareholder in Regeneron Pharmaceuticals, Inc.